Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 13, Issue SUPPL. 3, 1998, Pages 68-72

  Frazao, Joao M ^a,b   Chesney, Russell W ^c,d   Coburn, Jack W ^a,b,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d Bone Care International   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

1 hydroxyvitamin D2; Haemodialysis; Intact PTH; Secondary hyperparathyroidism; Therapeutic trial; Vitamin D

Indexed keywords

DOXERCALCIFEROL; PARATHYROID HORMONE; 1 ALPHA HYDROXYERGOCALCIFEROL; 1 ALPHA-HYDROXYERGOCALCIFEROL; ERGOCALCIFEROL; PHOSPHORUS;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; BLOOD; RENAL REPLACEMENT THERAPY; REVIEW;

ADMINISTRATION, ORAL; CLINICAL TRIALS; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS;

EID: 0031637872     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.suppl_3.68     Document Type: Conference Paper

References (32)

1. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-732
2. 3. Chem Pharm Bull 1982; 30: 4297-4303
3. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26(5): 852-860
4. DeLuca HF. Vitamin D metabolism and function. In: Gross R, Grumbach MM, Labhart A et al., eds. Monographs on Endocrinology. New York: Springer-Verlag, 1997: 1-78
5. Hunt RD, Garcia FG, Hegsted DM. Hypervitaminosis D in the new world monkeys. Am J Clin Nutr 1969; 22: 358-366
6. Sjöden G, Lindgren JU, DeLuca HF. Antirachitic activity of 1α-hydroxyergocalciferol and 1α-hydroxycholecalciferol in rats. J Nutr 1984; 114: 2043-2046
7. 3 in the rat. Proc Soc Exp Biol Med 1985; 178: 432-436
8. 2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3 osteoblastic cells. Res Exp Med 1991; 191: 235-242
9. 2 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 1994; 9: 607-614
10. 3 and calcium: short and long-term effects. Clin Endocrinol 1977; 7: 183S-189S
11. 3 on intestine and bone in glucocorticoid-treated patients. Clin Endocrinol 1977; 7: 177S-181S
12. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-323
13. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442
14. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150
15. Solal MC, Sebert JL, Boudailliez B et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991; 73: 516-524
16. 2 in suppressing 2° hyperparathyroidism in hemodialysis patients. Dial Transplant 1997; 26 (9): 583-595
17. 2) in 121 hemodialysis patients with secondary hyperparathyroidism: a phase 3 trial (abstract). J Am Soc Nephrol 1997; 12: 1781
18. Fischer ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993; 40: 216-220
19. Herrmann P, Ritz E, Schmidt-Gayk H et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 1994; 67: 48-53
20. Cannella G, Bonucci E, Rolla D et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46: 1124-1132
21. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F. The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991; 2: 1014-1020
22. Levine BS, Song MM. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: 488-496
23. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992; 19: 532-539
24. Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992; 42: 1191-1198
25. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
26. Gonella M, Calabrese G, Aleo AG, Vagelli G, Deambrogio P. Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients. Nephron 1995; 71: 350-353
27. Malberti F, Surian M, Cosci P. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 1992; 7: 822-828
28. Dressler R, Laut J, Lynn RI, Ginsberg N. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 1995; 43: 324-331
29. Llach F, Hervas J, Cerezo S. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 1995; 26: 845-851
30. 3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 1989; 53: 194-200
31. Ljunghall S, Althoff P, Fellström B et al. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis. Nephron 1990; 55: 380-385
32. 3 and low dialysate calcium. Kidney Int 1993; 43 [Suppl 41]: S121-S124